EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening

New drugs to tackle the next pathway or mutation fueling cancer are constantly proposed, but 97% of them are doomed to fail in clinical trials, largely because they are identified by cellular or in silico scre...

Source: Journal of Experimental and Clinical Cancer Research - January 10, 2024 Category: Cancer & Oncology Authors: Ambra Cappelletto, Edoardo Alf ì, Nina Volf, Thi Van Anh Vu, Francesca Bortolotti, Giulio Ciucci, Simone Vodret, Marco Fantuz, Martina Perin, Andrea Colliva, Giacomo Rozzi, Matilde Rossi, Giulia Ruozi, Lorena Zentilin, Roman Vuerich, Daniele Borin & hell Tags: Research Source Type: research